Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer
Cancer Research, June 2022
Kalra, Rashi, Chen, Ching Hui, Wang, Junkai, Salam, Ahmad Bin, Dobrolecki, Lacey E., Lewis, Alaina, Sallas, Christina, Yates, Clayton C., Gutierrez, Carolina, Karanam, Balasubramanyam, Anurag, Meenakshi, Lim, Bora, Ellis, Matthew J., Kavuri, Shyam M., Dobrolecki, Lacey E, Yates, Clayton C, Ellis, Matthew J, Kavuri, Shyam M
The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations have differential effects on endocrine therapy responsiveness, metastasis, and pan-HER TKI therapeutic sensitivity. The prevalence and prognostic significance may also depend on whether the HER2 mutant has arisen in the context of lobular versus ductal histology. The most highly recurrent HER2 mutant, L755S, was particularly resistant to neratinib but sensitive to the pan-HER TKI poziotinib, alone or in combination with fulvestrant. Poziotinib reduced tumor growth, diminished multi-organ metastasis, and inhibited mTOR activation more effectively than neratinib. Similar therapeutic effects of poziotinib were observed in both an engineered HER2L755S MCF7 model and a patient-derived xenograft harboring a HER2G778_P780dup mutation. Overall, these findings support the need for clinical evaluation of poziotinib for the treatment of HER2 mutant metastatic breast cancer.
|Members of the public||8||57%|
|Practitioners (doctors, other healthcare professionals)||1||7%|
|Science communicators (journalists, bloggers, editors)||1||7%|